Healthcare
Live Price
Offline$32.48
+0.03% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CymaBay Therapeutics, Inc. (CBAY) is a Healthcare stock with a market cap of $3.73B. The stock last traded around $32.48. Baseline metrics include revenue growth of 0.0%, EPS growth of +26.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +26.7%, free cash flow +13.4% with operating margin -327.2% and ROIC -24.9%. Valuation already assumes a fairly strong business story at price/sales 120.0. Stock Foundry combines CBAY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CBAY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CBAY Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CBAY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$102.2M
-110.1% YoY
Free Cash Flow
-$98.2M
-119.5% YoY
Revenue Growth
+0.0%
EPS Growth
+26.7%
Gross Margin
97.8%
Net Margin
-339.1%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 31M | 0 | 0 | 0 | 0 |
| Gross Profit | 30M | -710K | -688K | -632K | -800K |
| Operating Income | -102M | -93M | -88M | -53M | -108M |
| EBITDA | -86M | -92M | -87M | -50M | -108M |
| Net Income | -105M | -119M | -93M | -49M | -102M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 207M | 20M | 126M | 28M | 25M |
| Total Assets | 435M | 142M | 202M | 154M | 206M |
| Total Liabilities | 142M | 106M | 69M | 11M | 19M |
| Shareholder Equity | 292M | 36M | 133M | 143M | 186M |
| Total Debt | 114M | 91M | 52M | 2M | 2M |
| Net Debt | -92M | 71M | -74M | -26M | -23M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
98M
-118.9% YoY
Capital Expenditures
315K
-1400.0% YoY
Free Cash Flow
98M
-119.5% YoY
Key ratios
Gross Margin
97.8%
Operating Margin
-327.2%
Net Margin
-339.1%
ROE
-64.2%
Debt / Equity
0.39x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.